Cerebricon Ltd. Announces Release of New Model for Schizophrenia
30 June 2005
Kuopio, Finland
June 21st, 2005
Cerebricon Ltd., a contract rersearch organization specializing in preclinical models of CNS disease, announces the release of a new model for the study of pharmaceutical candidates aimed at treating schizophrenia.
The model, based on a PCP induced Schizophrenia, has a comprehensive battery of behavioral tests associated with it and has been fully validated, including the positive control Clozapine, in Cerebricon's proprietal laboratories, by Cerebricon Scientists.
